Neuroinflammation reduction

Neuroinflammation reduction is a therapeutic strategy rather than a single molecular target. It refers to interventions designed to suppress or modulate the inflammatory response within the central nervous system, primarily to slow or mitigate neurodegenerative processes. This strategy entails targeting cytokines (such as TNF-α, IL-1β, IL-6), intracellular signaling pathways (like NF-κB, PI3K/Akt, JAK/STAT), or cellular mediators (including microglia and astrocytes). Numerous drugs and biologics—including nonsteroidal anti-inflammatory drugs, targeted kinase inhibitors, monoclonal antibodies, and natural products—have been explored for their ability to reduce neuroinflammation in diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. In summary, "neuroinflammation reduction" is not a correct or sufficiently specific entry for a molecular target; any structured database entry should reference specific molecules, receptors, or pathways involved in neuroinflammation instead.

Other names

neuroinflammation suppressionanti-neuroinflammationneuroinflammatory pathway inhibition

Inhibition of pro-inflammatory cytokines/receptors (e.g., TNF-α, IL-1, IL-6); modulation of signal transduction pathways (e.g., PI3K/Akt, NF-κB, JAK/STAT, TLR4/Myd88); suppression of microglial activation; and promotion of anti-inflammatory cell phenotypes (e.g., M2 microglia).